Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 19:12 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer
NCT05163223 · Aston Sci. Inc. · PHASE2 · terminated · last registry update 2024-06-17 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Difficulty in recruiting patients” | – | Registry record, Aston Sci. Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CSF2RA in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-09-19Results posted on the registry: University of Washington, pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine + Sargramostim (NCT02780401)
- 2024-08-21Results posted on the registry: Hoffmann-La Roche, Atezolizumab + Paclitaxel (NCT03498716)
- 2024-08-21Also stopped (terminated): Hoffmann-La Roche, Atezolizumab + Paclitaxel (NCT03498716)
- 2023-12-12Results posted on the registry: Cancer Insight, LLC, NeuVax vaccine + Trastuzumab (NCT02297698)
- 2023-10-10Phase 3 first posted: BriaCell Therapeutics Corporation, SV-BR-1-GM + Cyclophosphamide (NCT06072612)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision